CVRx Logo_R_RGB_black.png
CVRx to Present at the Canaccord Genuity 41st Annual Growth Conference
29 juil. 2021 16h05 HE | CVRx, Inc.
MINNEAPOLIS, July 29, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally...
Gencaro Atrial Fibrillation Phase 2B Results Selected for Publication in Circulation: Arrhythmia and Electrophysiology
28 juil. 2021 08h00 HE | ARCA biopharma, Inc.
Analysis in full patient cohort shows Gencaro effect compared to standard of careIn the GENETIC-AF entire cohort of heart failure patients treated with Gencaro, compared to patients treated with...
CVRx Logo_R_RGB_black.png
CVRx to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call
21 juil. 2021 17h28 HE | CVRx, Inc.
MINNEAPOLIS, July 21, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally...
CVRx Welcomes Veteran Life Science Industry Leader Martha Shadan to its Board of Directors
12 juil. 2021 08h00 HE | CVRx, Inc.
MINNEAPOLIS, July 12, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally...
AMR Logo.png
Global Fluoroscopy Equipment Market To Garner $6.50 Billion By 2028: Allied Market Research
24 juin 2021 09h30 HE | Allied Market Research
Portland, OR, June 24, 2021 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Fluoroscopy Equipment Market generated $4.07 billion in 2020, and is estimated...
InCarda Logo.png
InCarda Therapeutics Announces Positive End-of-Phase 2 Meeting with FDA for InRhythm™ for Treatment of Atrial Fibrillation
23 juin 2021 08h05 HE | InCarda Therapeutics, Inc.
Single Pivotal Phase 3 Trial in Atrial Fibrillation Acceptable to Support Filing of New Drug Application Company on Track to Initiate Phase 3 RESTORE1 Study in Q3 2021 with Data Expected 2H 2022 ...
CVRx Logo_R_RGB_black.png
CVRx® Announces First Clinical Procedure with a New Ultrasound-Guided Implant Approach, the Latest Advancement in Barostim™ for the Treatment of Heart Failure Symptoms
10 juin 2021 11h19 HE | CVRx, Inc.
MINNEAPOLIS, June 10, 2021 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced the completion of the...
researchdrivelogo.jpg
Global Medical Device Manufacturing Outsourcing Market Predicted to Garner a Revenue of $104.3 Million at a CAGR of 10.3% during the Forecast Period, 2019-2026 - Exclusive Report [Pages-215] by Research Dive
09 juin 2021 09h36 HE | Research Dive
New York, USA, June 09, 2021 (GLOBE NEWSWIRE) -- According to a report published by Research Dive, the global medical device manufacturing outsourcing market is projected to register a revenue...
Reports and Data.jpeg-01
Computer Aided Detection (CAD) Market to Reach USD 1579.5 Million In 2028 | Reports and Data
09 juin 2021 09h00 HE | Reports and Data
New York, June 09, 2021 (GLOBE NEWSWIRE) -- Rising prevalence of chronic diseases and growing demand for computational assistance are key factors surging global market growth  Market size: USD...
InCarda Logo.png
InCarda Therapeutics Provides Corporate Update Highlighting New Phase 2 Data for InRhythm™ Program, Plans for Pivotal Phase 3 Study and Expansion of Senior Management Team
09 juin 2021 08h05 HE | InCarda Therapeutics, Inc.
Positive Data from Completed InRhythm Phase 2 Study Demonstrate Safe and Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Plans to Initiate RESTORE1: Single Pivotal Phase 3 Trial in...